Alnylam’s John Maraganore isn’t the only CEO to leave his post; CRISPR’s chief commercial officer takes the helm at a protein degradation player
The departure of a number of CEOs is the prevailing theme that kicks off this week’s installment: In a stunner, Alnylam CEO John Maraganore …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
